Filings & corporate actions
- 5 NovresultsResults · Q2 FY27 · consolidated and standalone+4.1%NSE
- 14 OctshareholdingShareholding · 30 Sept 2026+1.4%NSE
- 30 JulresultsResults · Q1 FY27 · consolidated and standalone-0.7%NSE
- 16 JulshareholdingShareholding · 30 Jun 2026+1.1%NSE
- 14 JuldividendDividend · ₹11.00 per share-6.2%
- 15 MayresultsResults · Q4 FY26 · consolidated and standalone-2.8%NSE
- 20 AprshareholdingShareholding · 31 Mar 2026-0.8%NSE
- 30 JanresultsResults · Q3 FY26 · consolidated and standalone+3.0%NSE
- 8 JanshareholdingShareholding · 31 Dec 2025-2.2%NSE
Reaction to results · all yearsrose on day 0 in 24 of 47 CSV
| Quarter | Filed | Day 0 | +5D | +20D | Rel vol |
|---|---|---|---|---|---|
| Q2 FY27 | 5 Nov 2026 | +4.1% | +0.9% | — | 20.7× |
| Q1 FY27 | 30 Jul 2026 | -0.7% | -1.5% | -8.3% | 8.2× |
| Q4 FY26 | 15 May 2026 | -2.8% | +3.5% | +12.2% | 1.1× |
| Q3 FY26 | 30 Jan 2026 | +3.0% | +5.2% | +8.9% | 4.9× |
| Q2 FY26 | 12 Nov 2025 | +1.4% | +0.7% | -4.6% | 0.9× |
| Q1 FY26 | 1 Aug 2025 | +12.5% | +0.1% | +5.6% | 84.7× |
| Q4 FY25 | 9 May 2025 | +6.2% | +12.0% | +12.7% | 0.4× |
| Q3 FY25 | 30 Jan 2025 | -2.4% | -9.3% | -25.5% | 4.4× |
| Q2 FY25 | 28 Oct 2024 | +6.1% | +7.8% | +17.4% | 13.0× |
| Q1 FY25 | 2 Aug 2024 | -1.1% | -13.3% | -24.6% | 1.7× |
| Q4 FY24 | 10 May 2024 | +4.6% | +7.1% | +12.2% | 12.0× |
| Q3 FY24 | 2 Feb 2024 | -3.9% | -7.0% | -7.2% | 3.7× |
| Q2 FY24 | 7 Nov 2023 | -3.0% | -8.6% | -12.4% | 4.2× |
| Q1 FY24 | 8 Aug 2023 | +3.7% | 0.0% | +3.1% | 22.7× |
| Q4 FY23 | 17 May 2023 | -6.0% | -10.7% | -10.5% | 7.4× |
| Q3 FY23 | 31 Jan 2023 | +5.8% | +3.7% | +0.1% | 19.1× |
| Q2 FY23 | 7 Nov 2022 | +0.4% | -1.9% | -5.9% | 1.4× |
| Q1 FY23 | 10 Aug 2022 | -6.3% | -13.6% | -12.2% | 12.2× |
| Q4 FY22 | 23 May 2022 | -1.5% | -1.7% | -4.7% | 0.4× |
| Q3 FY22 | 31 Jan 2022 | +4.7% | +2.6% | -8.2% | 10.2× |
| Q2 FY22 | 28 Oct 2021 | +0.2% | +2.0% | -8.1% | 1.3× |
| Q1 FY22 | 12 Aug 2021 | +9.7% | +6.6% | +16.4% | 33.3× |
| Q4 FY21 | 8 Jun 2021 | -2.3% | -5.4% | -7.3% | 0.4× |
| Q3 FY21 | 30 Jan 2021 | +4.3% | +3.8% | +2.7% | 1.4× |
| Q2 FY21 | 1 Nov 2020 | -2.4% | -0.6% | +1.7% | 0.8× |
| Q1 FY21 | 30 Jul 2020 | -0.1% | +7.5% | +12.4% | 0.6× |
| Q4 FY20 | 26 Jun 2020 | -3.7% | -3.4% | +1.8% | 1.5× |
| Q3 FY20 | 7 Feb 2020 | -3.8% | -7.7% | -15.9% | 2.8× |
| Q2 FY20 | 6 Nov 2019 | +1.7% | -4.2% | -4.9% | 6.4× |
| Q1 FY20 | 31 Jul 2019 | -1.3% | +5.7% | +5.2% | 4.4× |
| Q4 FY19 | 9 May 2019 | -0.1% | -3.7% | +19.6% | 0.5× |
| Q3 FY19 | 30 Jan 2019 | +2.7% | +16.0% | +7.6% | 1.8× |
| Q2 FY19 | 30 Oct 2018 | -1.1% | -1.0% | +1.6% | 0.1× |
| Q1 FY19 | 24 Aug 2018 | -1.2% | -1.9% | -13.6% | 1.7× |
| Q4 FY18 | 18 Jun 2018 | +0.6% | +2.7% | -4.2% | 0.4× |
| Q3 FY18 | 23 Jan 2018 | -3.5% | -6.9% | -5.5% | 0.8× |
| Q2 FY18 | 10 Nov 2017 | -3.6% | -1.5% | +24.4% | 1.1× |
| Q1 FY18 | 1 Aug 2017 | +0.3% | -7.1% | -14.2% | 0.1× |
| Q4 FY17 | 16 Jun 2017 | +0.3% | -3.2% | +18.4% | 0.5× |
| Q3 FY17 | 19 Jan 2017 | +0.1% | +1.1% | +0.4% | 2.3× |
| Q2 FY17 | 20 Oct 2016 | -0.8% | -0.4% | -5.9% | 21.8× |
| Q1 FY17 | 7 Sept 2016 | +1.2% | +0.5% | -3.8% | 1.7× |
| Q4 FY16 | 9 May 2016 | +20.0% | +15.5% | +17.5% | 18.5× |
| Q3 FY16 | 14 Feb 2016 | +10.6% | +9.7% | +19.2% | 0.7× |
| Q2 FY16 | 29 Oct 2015 | -3.1% | -6.4% | -1.2% | 0.4× |
| Q1 FY16 | 22 Jul 2015 | +0.9% | -2.9% | -7.5% | 1.8× |
| Q4 FY15 | 28 May 2015 | -1.2% | +3.0% | +13.8% | 3.5× |
| Average | +1.0% | -0.1% | +0.4% | ||
Close-to-close from the session before the filing could trade. Day 0 is the first session after it.
Growth · Q2 FY27
| CAGR | 2Y | 3Y | 4Y | 5Y | 6Y | 7Y |
|---|---|---|---|---|---|---|
| Revenue | +6.3% | +5.5% | — | +7.7% | +11.1% | — |
| Profit | +146.1% | +76.9% | — | +25.8% | +32.2% | — |
Key data
Delivery percentage
Over the last 20 sessions HESTERBIO settled 54.0% of its traded quantity, which is above average for an NSE equity. That is in line with its own one-year average of 56.0%. The latest session ranks higher than 31% of the 2,876 sessions on record for it.
What delivery percentage measuresScan the whole market on delivery
Dividends, deals & holders
Performance returns
| 1D | 1W | 1M | 3M | 6M | 1Y | |
|---|---|---|---|---|---|---|
| Price | -0.94% | +0.27% | +8.53% | -3.45% | +23.81% | +38.69% |
Valuation
Ownership
Quarterly results · consolidated
| Q3 FY26 | Q4 FY26 | Q1 FY27 | Q2 FY27 | |
|---|---|---|---|---|
| Revenue (₹ Cr) | 77.4 | 100.1 | 77.2 | 97.9 |
| YoY chg | +22.5% | +22.2% | -8.2% | +38.0% |
| Net profit (₹ Cr) | 9.3 | 16.5 | 96.7 | 20.6 |
| YoY chg | -18.4% | +973.7% | +459.3% | +44.0% |
| Net margin | 12.0% | 16.5% | 125.2% | 21.1% |
| EPS | 10.94 | 19.45 | 113.71 | 23.94 |
Shareholding over time
By quarter
30 Sept 2026 · promoter 44.28% · public 55.72%- Promoter
- Public and others
- Promoter
- 44.28%
- Public
- 55.72%
- Promoter change
- -9.45 pp
- Filed
- 14 Oct 2026
- FII
- 0.31%
- DII
- 0.08%
- Promoter pledged
- 0.00%
Who the public is
- Mutual funds
- 0.00%
- Insurance
- 0.00%
- FPI
- 0.30%
- Retail ≤ ₹2L
- 17.72%
- HNI > ₹2L
- 14.98%
- NRI
- 15.43%
- Bodies corporate
- 3.40%
- Shareholders
- 11,685
0.00 pp QoQ
0.00 pp QoQ
-0.01 pp QoQ
-0.70 pp QoQ
+0.40 pp QoQ
+10.03 pp QoQ
+0.69 pp QoQ
-2.3% QoQ
Major holders
As of 30 Sept 2026| Holder | Type | Holding | Shares |
|---|---|---|---|
| Rajiv Dinesh Gandhi | Promoter · Individual | 10.48% | 8.92L |
| Sanjiv Dinesh Gandhi | Promoter · Individual | 8.20% | 6.98L |
| Nina Rajiv Gandhi | Promoter · Individual | 8.19% | 6.96L |
| Shaila Bhupendra Gandhi | Promoter · Individual | 5.78% | 4.91L |
| Ravin Gandhi | Individual | 4.74% | 4.03L |
| Bela Gandhi | Individual | 4.71% | 4.01L |
| Bhupendra Vithaldas Gandhi | Promoter · Individual | 4.68% | 3.98L |
| Kuntal Hasmukhlal Shah | Individual | 3.17% | 2.70L |
| Biolink Healthcare Limited | Promoter · Corporate | 2.93% | 2.49L |
| Manish Jain | Individual | 2.88% | 2.45L |
Every promoter-group member, and each public holder above 1%, as filed.
Promoter and public shares of total equity, from the pattern filed each quarter. Institutional, pledge and public-breakdown figures come from the filing's XBRL, which most filings before Sep-2021 lack, so they are absent there rather than zero. Changes are against the previous filing.
Dividends
| Financial year | Payments | Declared | Adjusted |
|---|---|---|---|
| FY2026-27 | 1 | ₹11.00 | ₹11.00 |
| FY2025-26 | 1 | ₹7.00 | ₹7.00 |
| FY2024-25 | 1 | ₹6.00 | ₹6.00 |
| FY2023-24 | 1 | ₹8.00 | ₹8.00 |
| FY2022-23 | 1 | ₹10.00 | ₹10.00 |
| FY2021-22 | 1 | ₹10.00 | ₹10.00 |
| FY2020-21 | 1 | ₹6.60 | ₹6.60 |
| FY2019-20 | 1 | ₹7.00 | ₹7.00 |
| FY2018-19 | 3 | ₹10.00 | ₹10.00 |
| FY2017-18 | 2 | ₹6.30 | ₹6.30 |
| FY2016-17 | 2 | ₹4.10 | ₹4.10 |
| FY2015-16 | 2 | ₹6.10 | ₹6.10 |
| Ex-date | Record date | Declared | Adjusted |
|---|---|---|---|
| 14 Jul 2026 | — | ₹11.00 | ₹11.00 |
| 6 Aug 2025 | — | ₹7.00 | ₹7.00 |
| 22 Aug 2024 | — | ₹6.00 | ₹6.00 |
| 13 Sept 2023 | — | ₹8.00 | ₹8.00 |
| 11 Aug 2022 | — | ₹10.00 | ₹10.00 |
| 5 Aug 2021 | — | ₹10.00 | ₹10.00 |
| 27 Aug 2020 | — | ₹6.60 | ₹6.60 |
| 18 Jul 2019 | — | ₹7.00 | ₹7.00 |
| 9 Nov 2018 | — | ₹2.00 | ₹2.00 |
| 30 Aug 2018 | — | ₹2.00 | ₹2.00 |
| 2 Aug 2018 | — | ₹6.00 | ₹6.00 |
| 16 Nov 2017 | — | ₹4.00 | ₹4.00 |
| 20 Jul 2017 | — | ₹2.30 | ₹2.30 |
| 3 Nov 2016 | — | ₹3.00 | ₹3.00 |
| 21 Jul 2016 | — | ₹1.10 | ₹1.10 |
| 17 Mar 2016 | — | ₹3.00 | ₹3.00 |
| 10 Sept 2015 | — | ₹3.10 | ₹3.10 |
Rupees per share by ex-date, from NSE’s corporate actions; the record date is who was paid. Declared is the figure in the filing; adjusted restates it for splits and bonuses since, on the same basis as the price chart. Financial years run April to March.
Insider trades
- Insiders net, 30d
- ₹0
- Insiders net, 90d
- ₹0
- Promoters net, 90d
- ₹0
- Insider buyers, 90d
- 0
- Last promoter buy
- 6.7 years ago
- Disclosures on record
- 35
| Broadcast | Person | Side | Shares | Value | Price | Holding before → after | Stake | Regulation |
|---|---|---|---|---|---|---|---|---|
| 19 Mar 2020 | Shaila Bhupendra GandhiPromoter | Buy | 145 | ₹2.1L | 1,432.47 | 1.90L → 1.90L | 2.23%+0.00 pp | 7(2)told 17 Mar 2020 |
| 19 Mar 2020 | Bhupendra Vittaldas Gandhi HUFPromoter | Buy | 5 | ₹6,829 | 1,365.80 | 3.12L → 3.12L | 3.66%+0.00 pp | 7(2)told 17 Mar 2020 |
| 19 Mar 2020 | Bhupendra Vittaldas GandhiPromoter | Buy | 18 | ₹24,750 | 1,375.00 | 3.99L → 3.99L | 4.69%+0.00 pp | 7(2)told 17 Mar 2020 |
| 11 Dec 2019 | YASH RAJIV GANDHIPromoter | Buy | 100 | ₹1.6L | 1,580.84 | 3.1K → 3.3K | 0.04%+0.00 pp | 7(2)told 11 Dec 2019 |
| 1 Oct 2019 | Madhuri KapadiaPromoter | Sell | 903 | ₹15.9L | 1,763.80 | 2.06L → 2.05L | 2.41%-0.01 pp | 7(2)told 30 Sept 2019 |
| 27 Sept 2019 | Madhuri KapadiaPromoter | Sell | 29.8K | ₹5.6Cr | 1,861.33 | 2.36L → 2.06L | 2.43%-0.35 pp | 7(2)told 27 Sept 2019 |
| 14 Sept 2018 | BHAVNA JIGAR SHAHRelative | Buy | 106 | ₹1.3L | 1,224.79 | 744 → 850 | 0.01%+0.00 pp | 7(2)told 14 Sept 2018 |
| 7 Sept 2018 | BHAVNA JIGAR SHAHRelative | Buy | 112 | ₹1.4L | 1,245.39 | 632 → 744 | 0.01%+0.00 pp | 7(2)told 7 Sept 2018 |
| 31 Aug 2018 | BHAVNA JIGAR SHAHRelative | Buy | 100 | ₹1.3L | 1,251.50 | 532 → 632 | 0.01%+0.00 pp | 7(2)told 31 Aug 2018 |
| 12 Jun 2018 | YASH RAJIV GANDHIPromoter | Buy | 300 | ₹3.8L | 1,274.80 | 2.9K → 3.1K | 0.04%+0.00 pp | 7(2)told 12 Jun 2018 |
| 14 Mar 2018 | BHAVNA JIGAR SHAHRelative | Buy | 72 | ₹1.2L | 1,622.88 | 460 → 532 | 0.01%+0.00 pp | 7(2)told 14 Mar 2018 |
| 10 Mar 2018 | BHAVNA JIGAR SHAHRelative | Buy | 200 | ₹3.3L | 1,630.31 | 260 → 460 | 0.01%+0.00 pp | 7(2)told 10 Mar 2018 |
| 7 Mar 2018 | BHAVNA JIGAR SHAHRelative | Buy | 260 | ₹4.3L | 1,665.05 | — → 260 | 0.00% | 7(2)told 7 Mar 2018 |
| 8 Feb 2018 | YASH RAJIV GANDHIPromoter | Buy | 300 | ₹4.5L | 1,488.31 | 2.5K → 2.9K | 0.03%+0.00 pp | 7(2)told 8 Feb 2018 |
| 6 Feb 2018 | JIGAR PRAVINCHANDRA SHAHKMP | Buy | 100 | ₹1.4L | 1,444.99 | 1.1K → 1.2K | 0.01%+0.00 pp | 7(2)told 6 Feb 2018 |
| 16 Aug 2017 | YASH RAJIV GANDHIPromoter | Buy | 750 | ₹6.8L | 904.94 | 1.8K → 2.5K | 0.03%+0.01 pp | 7(2)told 16 Aug 2017 |
| 24 Mar 2017 | Hester Coatings LLPPromoter | Sell | 90.0K | ~₹6.6Cr | 728.60 | 90.0K → — | 0.00% | 7(2)told 24 Mar 2017 |
| 24 Mar 2017 | Rajiv GandhiPromoter | Buy | 90.0K | ~₹6.6Cr | 728.60 | 8.59L → 9.49L | 11.16%+1.06 pp | 7(2)told 24 Mar 2017 |
| 20 Jul 2016 | YASH GANDHIPromoter | Buy | 700 | ₹5.1L | 723.18 | 1.1K → 1.8K | 0.02%+0.01 pp | 7(2)told 19 Jul 2016 |
SEBI insider-trading disclosures, equity only. Dated by the day NSE broadcast them; the trade itself is often weeks earlier. The figures count promoters, directors and KMPs buying or selling on the exchange — not ESOPs, gifts, transfers within the promoter group or pledges. Stake is the holding after, as filed; the change beneath it scales that by the share counts before and after. Regulation is the PIT clause cited, and “told” the day the insider informed the company.
How the insider figures are countedPromoters buying in the open market, market-wideEvery stock on this session
Takeover-code disclosures
Filed under SEBI’s takeover regulations when a holding crosses 5% of the company, and again with every 2% it moves after that. Shares and percentages as filed.
Every stock on this session →Short selling, lending & margin
Shares bought on broker margin funding (MTF) and still held at the day’s end, and the amount brokers have lent against them.
Exchange surveillance
No surveillance measure applies to HESTERBIO.
Price band: 20% · not in the F&O ban.
From NSE’s daily surveillance, price-band and position-limit files. A stock enters the F&O ban when open interest passes 95% of its market-wide position limit and leaves it below 80%; until then no new positions can be opened. CSV: measures · band changes.
Every stock on this session →Financials · quarterly statement
| Q3 FY24 | Q4 FY24A | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25A | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26A | Q1 FY27 | Q2 FY27 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from operations | 67.0 | 79.3 | 82.3 | 83.7 | 63.2 | 81.9 | 84.1 | 71.0 | 77.4 | 100.1 | 77.2 | 97.9 | |
| Other income | 1.0 | 4.1 | 1.2 | 1.8 | 7.8 | (7.0) | 2.3 | 9.7 | 0.7 | (3.0) | 1.6 | 1.5 | |
| Total income | 68.0 | 83.4 | 83.5 | 85.5 | 71.0 | 75.0 | 86.4 | 80.7 | 78.1 | 97.1 | 78.9 | 99.4 | |
| Total expenses | 62.8 | 74.0 | 73.8 | 74.6 | 58.6 | 72.5 | 67.3 | 65.8 | 65.9 | 76.8 | 64.6 | 75.3 | |
| └ Finance costs | 2.2 | 6.9 | 5.0 | 5.9 | (3.8) | 5.6 | 1.8 | 2.2 | 1.8 | 5.1 | 3.1 | 3.0 | |
| └ Depreciation | 3.7 | 3.7 | 4.1 | 4.2 | 4.3 | 4.2 | 4.2 | 4.4 | 4.4 | 5.9 | 7.0 | 7.1 | |
| Profit before tax | 5.2 | 9.4 | 9.7 | 10.9 | 12.4 | 2.4 | 19.1 | 14.9 | 12.2 | 23.2 | 99.6 | 24.6 | |
| Tax expense | 2.4 | 3.5 | 3.1 | 3.5 | 2.0 | 2.2 | 2.9 | 2.7 | 4.2 | 8.5 | 5.0 | 5.8 | |
| Net profit | 4.0 | 6.4 | 7.5 | 8.4 | 11.4 | 1.5 | 17.3 | 14.3 | 9.3 | 16.5 | 96.7 | 20.6 | |
| EPS | 4.73 | 7.52 | 8.80 | 9.86 | 13.41 | 1.82 | 20.33 | 16.85 | 10.94 | 19.45 | 113.71 | 23.94 | |
| Net margin | 6.00% | 8.07% | 9.10% | 10.03% | 18.05% | 1.88% | 20.56% | 20.19% | 12.03% | 16.53% | 125.23% | 21.07% | |
| PBT margin | 7.77% | 11.84% | 11.83% | 13.04% | 19.60% | 2.97% | 22.75% | 20.97% | 15.77% | 23.21% | 129.00% | 25.07% | |
| Tax rate | 45.95% | 36.99% | 31.92% | 31.86% | 15.80% | 90.51% | 15.11% | 18.17% | 34.52% | 36.77% | 4.97% | 23.72% |
A audited · R restated by a later filing · negatives in parentheses. EPS and the share count are restated onto the same split-adjusted basis as the price chart, so they can be read against it; every rupee figure is exactly as filed. The balance sheet and cash flow arrive only with the half-year and annual filings, and are in their own section below. Latest filed 5 Nov 2026.
Balance sheet & cash flow · half-yearly
Balance sheet
| FY23 | H1 FY24 | FY24 | H1 FY25 | FY25 | H1 FY26 | FY26 | H1 FY27 | Trend | |
|---|---|---|---|---|---|---|---|---|---|
| Total assets | 670.0 | 683.0 | 662.3 | 669.3 | 653.4 | 675.2 | 677.9 | 683.3 | |
| Current assets | 227.6 | 238.3 | 214.6 | 222.2 | 195.2 | 203.7 | 208.6 | 221.8 | |
| └ Cash & equivalents | 13.2 | 13.0 | 12.7 | 13.6 | 5.6 | 6.3 | 2.8 | 23.5 | |
| └ Other bank balances | 1.7 | 1.4 | 2.6 | 3.2 | 1.6 | 1.6 | 3.8 | 3.7 | |
| └ Current investments | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| └ Trade receivables | 79.6 | 98.9 | 78.6 | 94.1 | 73.2 | 92.6 | 95.4 | 81.7 | |
| └ Inventories | 84.8 | 80.4 | 75.6 | 67.2 | 70.4 | 65.9 | 72.5 | 78.9 | |
| Total equity | 288.5 | 291.5 | 302.9 | 314.2 | 326.7 | 351.0 | 367.8 | 475.3 | |
| └ Attributable to owners | 279.7 | 281.9 | 291.8 | 301.8 | 314.3 | 337.9 | 360.2 | 467.8 | |
| └ Non-controlling interest | 8.8 | 9.6 | 11.1 | 12.4 | 12.4 | 13.1 | 7.6 | 7.6 | |
| └ Share capital | 8.5 | 8.5 | 8.5 | 8.5 | 8.5 | 8.5 | 8.5 | 8.5 | |
| Borrowings | 268.2 | 267.3 | 239.0 | 239.1 | 207.8 | 207.6 | 188.3 | 102.1 | |
| └ Current | 83.3 | 77.0 | 57.3 | 84.1 | 74.4 | 94.1 | 98.3 | 58.8 | |
| └ Non-current | 184.9 | 190.3 | 181.8 | 155.0 | 133.4 | 113.6 | 90.0 | 43.4 | |
| Trade payables | 30.0 | 30.0 | 26.4 | 24.7 | 29.4 | 28.5 | 24.7 | 22.9 | |
| Current liabilities | 148.7 | 131.7 | 105.8 | 126.8 | 125.2 | 141.4 | 152.5 | 98.9 | |
| Total liabilities | 381.4 | 391.5 | 359.5 | 355.0 | 326.7 | 324.1 | 310.2 | 207.9 | |
| Net debt | 253.3 | 252.8 | 223.7 | 222.3 | 200.6 | 199.7 | 181.7 | 74.9 | |
| Debt / equity | 0.93 | 0.92 | 0.79 | 0.76 | 0.64 | 0.59 | 0.51 | 0.21 | |
| Current ratio | 1.53 | 1.81 | 2.03 | 1.75 | 1.56 | 1.44 | 1.37 | 2.24 |
Cash flow, year to date
| FY23 | H1 FY24 | FY24 | H1 FY25 | FY25 | H1 FY26 | FY26 | H1 FY27 | Trend | |
|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 23.6 | 5.7 | 48.1 | 24.1 | 64.5 | 17.5 | 64.1 | 49.0 | |
| └ Capex | (77.8) | (13.9) | (24.4) | (13.0) | (20.6) | (8.4) | (17.8) | (4.2) | |
| Free cash flow | (54.2) | (8.3) | 23.7 | 11.1 | 43.9 | 9.1 | 46.3 | 44.8 | |
| Investing cash flow | (77.0) | (13.7) | (22.7) | (13.0) | (19.0) | (2.3) | (3.3) | (2.8) | |
| Financing cash flow | 41.8 | 9.0 | (26.0) | (10.1) | (51.7) | (15.6) | (48.8) | (24.4) | |
| └ Dividends paid | (8.5) | (6.8) | (6.8) | (5.1) | (5.2) | (6.0) | (6.0) | (9.3) | |
| └ Buybacks | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Net change in cash | (11.6) | 1.0 | (0.6) | 1.0 | (6.2) | (0.4) | 12.1 | 20.8 |
From the half-year and annual results filings: the balance sheet from September 2022, the cash flow from September 2020. Those are when NSE’s XBRL began to carry each statement; earlier filings have it only in the attached PDF. Cash flow columns are year to date, so an H1 column covers April to September and an FY column the full year. Outflows are in parentheses. Net debt is borrowings less cash, bank balances and current investments; for banks, NBFCs and insurers it, debt to equity and the current ratio are left blank because their statements are not built that way.
Announcements & board meetings
As the company filed them with NSE, newest first. Board meetings are dated by the meeting, which is usually a week or more after the intimation.
Every stock on this session →HESTERBIO at a glance
- HESTERBIO closed at ₹2,329.9 on 20 Nov 2026, -0.94% on the day, +38.7% over one year, 13.2% below its 52-week high of ₹2,683.6.
- Delivery was 55.2% of traded quantity on 20 Nov 2026, the 31st percentile of its own 2,876 sessions with a reading (20-session average 54.0%, 1-year average 56.0%).
- Market capitalisation is ₹1,982 crore at a trailing P/E of 13.9 (trailing EPS ₹167.03).
- Q2 FY27 results (consolidated, filed 5 Nov 2026): revenue ₹98 crore (+38.0% year on year), net profit ₹21 crore (+44.0%); the price moved +4.1% on the first session after.
- Promoters held 44.28% at 30 Sept 2026, down 9.45 percentage points on the previous filing.
- Q3 FY27 results are expected between 30 Jan 2027 and 2 Feb 2027, going by past filing dates — an estimate, not an announcement.
About
Prices are adjusted for splits and bonuses. Delivery figures come from NSE’s daily reports and are unavailable for older sessions. Sourced from the eod2 dataset, last updated 20 Nov 2026.
More in Pharmaceuticals & Biotechnology
- DIDIVISLABDivi's Laboratories Limited11,180.50+0.02%
- LALAURUSLABSLaurus Labs Limited2,294.60-0.49%
- SUSUNPHARMASun Pharmaceutical Industries Limited1,884.90-0.79%
- ACACUTAASAcutaas Chemicals Limited3,833.50-3.61%
- SASAILIFESai Life Sciences Limited1,800.70+0.69%
- PPPPLPHARMAPiramal Pharma Limited239.30-0.15%
- DRDRREDDYDr. Reddy's Laboratories Limited1,390.20-0.76%
- GLGLENMARKGlenmark Pharmaceuticals Limited2,648.00+1.51%
- AUAUROPHARMAAurobindo Pharma Limited1,799.00-0.37%
- CICIPLACipla Limited1,415.00-0.25%
- ZYZYDUSLIFEZydus Lifesciences Limited1,200.00-0.24%
- MAMANKINDMankind Pharma Limited2,665.00+1.37%
All Pharmaceuticals & Biotechnology stocks on the NSEAll Healthcare stocks on the NSE